Educating Your Patients

The NHLBI* recommends inhaled corticosteroids (ICSs) as an appropriate first-line treatment for control of persistent pediatric asthma.¹ This section provides information that may be useful in your practice, as you work with parents and caregivers to develop a plan for controlling persistent pediatric asthma symptoms.

In this section

AsthmaKidCare™ Pro
Find a library of educational resources you can customize and send to parents and caregivers as a follow-up to your visits.

Using the Asthma Action Plan
Prepare patients and caregivers with a plan for maintaining control of asthma symptoms.

Seasonal Asthma Triggers
Be sure the parents and caregivers in your practice are aware of — and taking steps to reduce the impact of — seasonal triggers.

Talking to Parents About ICSs
Help parents and caregivers both evaluate the benefits of ICS treatment and understand the risks.

Patient & Parent Support
Hear what parents and caregivers say about their fears, concerns, and successes in dealing with their child’s asthma, and find online resources and support services for patients and their parents.

Footnotes

* National Heart, Lung, and Blood Institute

Enlarge Text:

Print:

Educational resources for families in your care.

Links to learn about other asthma treatment options for patients:

Indication

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

Important Safety Information

Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

PULMICORT RESPULES, like other inhaled corticosteroids, may impact the hypothalamic-pituitary-adrenal axis, especially in susceptible individuals, in young children, and in patients given high doses for prolonged periods.

Particular care is needed for patients who are transferred from systemically active corticosteroids to less systemically available corticosteroids, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids (see WARNINGS in full Prescribing Information).

Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

Common adverse events reported in clinical trials, regardless of relationship to treatment, included respiratory infection, rhinitis, coughing, otitis media, viral infection, gastroenteritis, ear infection, oral thrush/candidiasis, and epistaxis.

Please see accompanying full Prescribing Information (PDF).

Site Map | References | Contact Us